

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Stacie Weeks, JD MPH Administrator

## **Silver State Scripts Board Meeting Minutes**

**Date of Meeting**: Thursday, June 20, 2024, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record		Notes
1. Closed Executive Session			
a. Call to Order and Roll Call	Chairperson Mark Decerbo called the m June 20, 2024.  Chairperson Decerbo took the roll.	<ul> <li>DHCFP Staff Present were as follows:</li> <li>Brown, Antonio, Chief of Pharmacy &amp; DME</li> </ul>	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm. D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>	Present Absent	<ul> <li>Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>Flowers, Ellen, Social Services Program Specialist II</li> <li>Palomino, Bonnie, Program Officer I</li> <li>Athanasia Dalacas, Deputy Attorney General</li> <li>NMAP Staff Present were as follows:</li> </ul>

			<ul> <li>Cowan, Sarah, Health Program Specialist I</li> </ul>
			<ul> <li>Magellan (Prime) Staff</li> <li>Present were as follows:         <ul> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> </ul> </li> <li>Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> <li>Martinez, Chris, Sr. Business Analyst</li> <li>Perez, Melissa, Sr. Business Analyst</li> </ul>
b.	Financial Review of Drug Classes with Proposed Changes	Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the Financial Review of Drug classes with proposed changes up for review.  Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.  Dr. Deoliveira presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with proposed changes in PDL status.  • Vasodilators – Oral  Dr. Deoliveira presented the financial review of the New Drug Classes Being Reviewed for Proposed Addition, noting the products with proposed changes in PDL status.  • Topical Anti-infectives, vaginal	

	Dr. Mishra presented the financial revie		_
	with proposed changes, noting the prod	ucts with proposed cha	nges in
	PDL status.		
	Skeletal Muscle Relaxants		
	<ul> <li>Biguanides</li> </ul>		
	Fibric Acid Derivatives		
	<ul> <li>Proton Pump Inhibitors (PPIs)</li> </ul>		
	Functional Gastrointestinal Disord	der Drugs	
	ADHD Agents		
	Phosphate Binding Agents		
2. Open Public Meeting			
a. Call to Order and Roll Call	Chairperson Decerbo called the meetin	g to order at 1:45 p.m.	
	20, 2024.		follows:
	A guarum was present		Brown, Antonio, Chief of      Bharman & DM5
	A quorum was present.		Pharmacy & DME  • Clemons, Roshanda, MD,
	Chairperson Decerbo took the roll.		Clemons, Roshanda, MD,     Medicaid Medical Director
	champerson becerbo took the roll.	Present Absent	Flowers, Ellen, Social
	Mark Decerbo, Pharm.D., Chair		Services Program
	Kate Ward, Pharm.D., Vice Chair		Specialist II
	·		Palomino, Bonnie,
	Joseph Adashek, MD		Program Officer I
	Mark Crumby, Pharm. D.		<ul> <li>Dalacas, Athanasia,</li> </ul>
	Elizabeth Gonzalez, Pharm.D.		Deputy Attorney General
	Sapandeep Khurana, MD		, , ,
	Isabella Niezborala, Pharm.D.		NMAP Staff Present were as
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>		follows:
	<ul> <li>Aditi Singh, MD</li> </ul>		<ul> <li>Cowan, Sarah, Health</li> </ul>
			Program Specialist I
			Magellan (Prime) Staff
			Present were as follows:

			<ul> <li>Deoliveira, Brittany,         Pharm.D., Clinical Account         Manager</li> <li>Mishra, Raj, Pharm.D.,         Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir.         Clinical Account Services</li> <li>Martinez, Chris, Sr.         Business Analyst</li> <li>Perez, Melissa, Sr.         Business Analyst</li> <li>The public attendee list is included as Attachment A.         Note: Participants may not have chosen to reveal their</li> </ul>
			identity, and in the absence of a sign-in sheet, the attendee
			list's accuracy is not assured
b.	Approval for previous  Meeting Minutes from March 21, 2024.	By unanimous consent, the minutes were approved.	
C.	Public Comments	Telephonic and web comment was called for, and the phone lines were opened.  Public comment was provided by Lea Case on behalf of the Nevada	
		Psychiatric Association	
d.	Status Update by DHCFP	Chief of Pharmacy & DME, Antonio Brown, provided an announcement.	
		<ul> <li>Pharmacy Services is excited to welcome Bonnie Palomino as a new Program Officer. Bonnie will be mainly overseeing the Pharmacy Lock-In Program for the fee- for- service program and</li> </ul>	

	providing support to both of our Silver State Scripts Board and our	
	Drug Utilization Review Board.	
	DHCFP is also in the process of hiring an additional team member,	
	in order to have a fully staffed unit.	
	The division would like to invite everyone to attend our upcoming	
	DUR board meeting, which is going to be held July 18, 2024. During	
	this meeting, will be discussing our new clinical criteria for Wegovy	
	(semaglutide), due to its recent FDA approved indication to reduce	
	the risk of major adverse cardiovascular events in adults with	
	established cardiovascular disease and either obesity or	
	overweight. Please know this coverage specific to the new	
	indication only. Nevada Medicaid currently excludes coverage for	
	weight loss agents. For additional details about the meeting,	
	please visit our DHCFP website.	
e. Status Update by NMAP	Health Program Specialist, Sarah Cowan, provided an announcement.	
	<ul> <li>As of May 1st, 2024, NMAP has added doxycycline monohydrate</li> </ul>	
	to the formulary.	
	<ul> <li>Tory Johnson is no longer a Section Manager, and no longer</li> </ul>	
	works for the state of Nevada.	
3. Clinical Presentations		
A. For Possible Action: Discussion		
and possible adoption of		
Vasodilators – Oral.		
i. <u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were	
	opened.	
	Public comment was provided by Amy Hale, a pharmacist with Johnson	
	and Johnson.	
ii. Drug class review	Dr. Deoliveira discussed Opsynvi, the new product within this drug class.	
presentation by	She presented the availability within the drug class and noted the	
Magellan (Prime).	indication, mechanism of action, and efficacy studies.	
•	, ,	

	Dr. Deoliveira recommended the Botherapeutically equivalent.	oard cor	nsider t	he class clinicall	y and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in	Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Magellan (Prime), and Board Member Leana Ramirez seconded the motion.  A vote was taken, and the results were as follows from members in					
class.	attendance (in favor, against, and a	bstentic	ns wh	ere applicable):		
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	×				
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$				
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
	Mark Crumby, Pharm.D.			$\boxtimes$		
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
	Sapandeep Khurana, MD	$\boxtimes$				
	• Isabella Niezborala, Pharm.D.			$\boxtimes$		
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$				
	Aditi Singh, MD			$\boxtimes$		
v. Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended adding Opsynvi on the PDL as non-preferred. Also recommended moving brand Revatio tablet and suspension from preferred to non-preferred and moving its generic sildenafil tablet and suspension from non-preferred to preferred. Also recommended leaving Tracleer tablet as preferred and defining Tracleer tablet for suspension as non-preferred.					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Elizabeth Gonzalez seconded the motion.					

	attendance (in favor, against, and a	hstanti	anc wh	oro applicable):
	accentiance (in lavoi, against, and a	טטנפוונונ	יוואא פווע	ere applicable).
		Yes	No	Abst.
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$		
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$		
	Joseph Adashek, MD			$\boxtimes$
	Mark Crumby, Pharm.D.			$\boxtimes$
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$		
	Sapandeep Khurana, MD	$\boxtimes$		
	• Isabella Niezborala, Pharm.D.			$\boxtimes$
	Leana Ramirez, Pharm.D.	$\boxtimes$		
	Aditi Singh, MD			$\boxtimes$
and possible adoption of Topical Anti-infectives, vaginal.				
i. <u>Public comment</u>	Telephonic and web comment was opened.	called fo	or, and	the phone lines were
	No public comment was provided.			
ii. Drug class review presentation by Magellan (Prime).	Dr. Deoliveira discussed Topical Ant new drug class. She presented the a noted the indication, mechanism of Dr. Deoliveira recommended the Botherapeutically equivalent.	vailabil action,	ity with and ef	hin the drug class and fficacy studies.
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Chairperson Decerbo moved to acce therapeutically equivalent presente Member Ramirez seconded the mot	d by M		

_							
	equivalency of agents in class.		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
	5.3.55.	attendance ( raver) againes, and e					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		Mark Crumby, Pharm.D.			$\boxtimes$		
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
		Sapandeep Khurana, MD	$\boxtimes$				
		<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>			$\boxtimes$		
		Leana Ramirez, Pharm.D.	$\boxtimes$				
		Aditi Singh, MD			$\boxtimes$		
	iv. Presentation of	Dr. Deoliveira recommended addin	•		·		
	recommendations for	metronidazole (generic for Vandazo					
	PDL inclusion by Magellan (Prime).	preferred and adding clindamycin, non-preferred.	Cimaess	se, van	luazoie aliu xaciato as		
	Wagenan (Frince).	non preferred.					
-	v. Discussion by Board and	Vice Chairperson Kate Ward moved	to app	rove th	ne proposed changes as		
	action by Board for	presented by Magellan (Prime) and	Board	Memb	er Sapandeep Khurana		
	approval of drugs for inclusion on the PDL.	seconded the motion.					
		A vote was taken, and the results w	ere as f	ollows	from members in		
			attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		Mark Crumby, Pharm.D.			$\boxtimes$		
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$				

	Isabella Niezborala, Pharm.D.			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
<b>C.</b> For Possible Action: Discussion					
and possible adoption of					
Skeletal Muscle Relaxants.					
i D. His Comment	Tile de circula de la companya de companya	111 6		de de la contraction	
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called to	or, and	the phone line	es were
	No public comment was provided.				
ii. Drug class review	Dr. Deoliveira recommended the Bo	oard cor	nsider 1	he class clinica	lly and
presentation by	therapeutically equivalent.				
Magellan (Prime).					
iii. Discussion by Board	Chairperson Decerbo moved to acc	Chairperson Decerbo moved to accept the class as clinically and			
and action by Board to	therapeutically equivalent presente	•		•	ice
approve	Chairperson Ward seconded the m	otion.			
clinical/therapeutic					
equivalency of agents in	A vote was taken, and the results w				
class.	attendance (in favor, against, and a	bstenti	ons wh	ere applicable)	:
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
	Joseph Adashek, MD			$\boxtimes$	
	Mark Crumby, Pharm.D.			$\boxtimes$	
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.			$\boxtimes$	
	Leana Ramirez, Pharm.D.	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	

re PC	resentation of ecommendations for DL inclusion by lagellan (Prime).	Dr. Deoliveira recommended adding and carisoprodol 250 mg as non-pre chlorzoxazone 375 mg, 500 mg, and chlorzoxazone 250 mg as non-prefe				
	oard Member omments	Dr. Khurana provided a comment.				
ac ap	iscussion by Board and ction by Board for opproval of drugs for clusion on the PDL.	Vice Chairperson Ward moved to appresented by Magellan (Prime) with chlorzoxazone 500 mg as preferred mg to non-preferred and board me  A vote was taken, and the results was attendance (in favor, against, and a				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	×			
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
		Mark Crumby, Pharm.D.			$\boxtimes$	
		<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>	$\boxtimes$			
		Sapandeep Khurana, MD	$\boxtimes$			
		Isabella Niezborala, Pharm.D.			$\boxtimes$	
		• Leana Ramirez, Pharm.D.	$\boxtimes$			
		<ul> <li>Aditi Singh, MD</li> </ul>				
	ssible Action: Discussion ssible adoption of lides.					
i. <u>Pul</u>	blic Comment	Telephonic and web comment was opened.	the phone lines were			
		No public comment was provided.				

ii.	Drug class review presentation by Magellan (Prime).	Dr. Deoliveira recommended the Bo therapeutically equivalent.	1			
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Magellan (Prime) and Board Member Ramirez seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
		<ul> <li>Mark Crumby, Pharm.D.</li> </ul>			$\boxtimes$	
		• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
		• Isabella Niezborala, Pharm.D.			$\boxtimes$	
		<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$			
		<ul> <li>Aditi Singh, MD</li> </ul>			$\boxtimes$	
iv.	Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended adding Riomet ER suspension on the PDL as preferred and adding metformin 625 mg (oral) as non-preferred.				. as
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board member Ramirez moved to approve the proposed changes as presented by Magellan (Prime) and Chairperson Decerbo seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				е

		Yes	No	Abst.	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	<ul> <li>Mark Crumby, Pharm.D.</li> </ul>			$\boxtimes$	
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
	• Isabella Niezborala, Pharm.D.			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
E. For Possible Action: Discussion and possible adoption of Fibric Acid Derivatives.					
i. <u>Public Comment</u>	Telephonic and web comment was opened.  No public comment was provided.				
ii. Drug class review presentation by Magellan (Prime).	Dr. Deoliveira recommended the Bo therapeutically equivalent.				
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairperson Decerbo moved to accomply the therapeutically equivalent presented Ward seconded the motion.  A vote was taken, and the results we attendance (in favor, against, and a				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	⊠			
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$		П	
1	- Nace vvara, i narri.D., vice chair	~ `		<b>□</b>	1

_							
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		<ul> <li>Mark Crumby, Pharm.D.</li> </ul>			$\boxtimes$		
		<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>	$\boxtimes$				
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$				
		<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>			$\boxtimes$		
		<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$				
		Aditi Singh, MD			$\boxtimes$		
	iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended keeping the generic Antara, Lofibra, and Tricor as the preferred fenofibrate products and moving generic for Fenoglide and Lipofen to non-preferred. Recommend changing "fenofibric" verbiage to "fenofibric acid" for clarity on the PDL. Also recommended keeping the generic Trilipix as our preferred fenofibric acid product, while moving the generic for Fibricor to non-preferred. Also recommend moving brand Lipofen from non-preferred to preferred.					
	v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Khurana seconded the motion.					
		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		Mark Crumby, Pharm.D.			$\boxtimes$		
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
		Sapandeep Khurana, MD	$\boxtimes$				
		<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>	П		$\boxtimes$		

	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$					
	<ul> <li>Aditi Singh, MD</li> </ul>			X			
<b>F.</b> For Possible Action: Discussion							
and possible adoption of							
Proton Pump Inhibitors (PPIs).							
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.						
	No public comment was provided.						
ii. Drug class review		Dr. Deoliveira recommended the Board consider the class clinically and					
presentation by Magellan	therapeutically equivalent.						
(Prime).							
iii. Discussion by Board and	Chairperson Decerbo moved to accept the class as clinically and						
action by Board to	therapeutically equivalent presente	•	agellan	(Prime) a	nd Board		
approve	Member Ramirez seconded the mo	tion.					
clinical/therapeutic equivalency of agents in	A vote was taken, and the results w	ara as fo	llows	from mom	hars in		
class.	attendance (in favor, against, and a						
				o. o appo.			
		Yes	No	Abst.			
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$					
	<ul> <li>Kate Ward, Pharm.D., Vice Chair</li> </ul>	$\boxtimes$					
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$			
	<ul> <li>Mark Crumby, Pharm.D.</li> </ul>			$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$					
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$					
	• Isabella Niezborala, Pharm.D.			$\boxtimes$			
	Leana Ramirez, Pharm.D.	$\boxtimes$					
	Aditi Singh, MD			$\boxtimes$			

iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira announced that Prilos PDL, as the manufacturer no longer rebate program. Also recommended non-preferred and adding its general Also recommend moving Nexium per to non-preferred.				
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Ramirez moved to a presented by Magellan (Prime) and motion.				
	A vote was taken, and the results we attendance (in favor, against, and a				
	accendance (in ravor) against, and a		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	<ul> <li>Kate Ward, Pharm.D., Vice Chair</li> </ul>	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>				
	<ul> <li>Mark Crumby, Pharm.D.</li> </ul>				
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
	• Isabella Niezborala, Pharm.D.			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
G. For Possible Action: Discussion and possible adoption of Functional Gastrointestinal Disorder Drugs					
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called fo	or, and	the phone lines were	

		No public comment was provided.				
_	class review ntation by Magellan e).	Dr. Deoliveira recommended the Bo therapeutically equivalent.	d			
action appro clinica	ral/therapeutic valency of agents in	Chairperson Decerbo moved to access therapeutically equivalent presented Ward seconded the motion.  A vote was taken, and the results we attendance (in favor, against, and all	d by Ma	agellan ollows t	(Prime) and Vice Ch	air
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	×			
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
		Mark Crumby, Pharm.D.			$\boxtimes$	
		• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
		• Isabella Niezborala, Pharm.D.			$\boxtimes$	
		• Leana Ramirez, Pharm.D.	$\boxtimes$			
		<ul> <li>Aditi Singh, MD</li> </ul>			$\boxtimes$	
recon	entation of mmendations for PDL sion by Magellan ne).	Dr. Deoliveira recommends moving preferred and moving its generic lub preferred.				
action appro	ussion by Board and n by Board for oval of drugs for sion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Ramirez seconded the motion.  A vote was taken, and the results were as follows from members in				

	attandance (in favor against and a				
	attendance (in favor, against, and a				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	Mark Crumby, Pharm.D.			$\boxtimes$	
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	• Isabella Niezborala, Pharm.D.			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
<ul> <li>H. For Possible Action: Discussion and possible adoption of ADHD Agents.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was opened.  No public comment was provided.				
ii. Drug class review presentation by Magellan (Prime).	Dr. Deoliveira recommended the Both therapeutically equivalent.				
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairperson Decerbo moved to accomply the the therapeutically equivalent presented Member Ramirez seconded the moon A vote was taken, and the results was tendance (in favor, against, and a				
5.055.	2333020000 ( 13131) against, and a				

		Mark Decerbo, Pharm.D., Chair	$\boxtimes$					
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$					
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$			
		Mark Crumby, Pharm.D.			$\boxtimes$			
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$					
		Sapandeep Khurana, MD	$\boxtimes$					
		• Isabella Niezborala, Pharm.D.			$\boxtimes$			
		Leana Ramirez, Pharm.D.	$\boxtimes$					
		Aditi Singh, MD			$\boxtimes$			
	December 1				11 .	l. ED		
IV.	Presentation of recommendations for PDL	Dr. Deoliveira recommended movi						
	inclusion by Magellan		(generic for Adderall XR) from non-preferred to preferred and also including generic Concerta (methylphenidate ER) on the preferred drug					
	(Prime).	list.	priemad	ite Livi	on the pr	ererred drug		
	(*)							
٧.	Board Member comments	Vyvanse utilization was presented	to the b	oard m	embers.			
vi.	Discussion by Board and	Chairperson Decerbo moved to app				-		
	action by Board for	presented by Magellan (Prime) and the motion.	Board I	Memb	er Khuran	a seconded		
	approval of drugs for inclusion on the PDL.	the motion.						
	merasion on the 1 DE.	A vote was taken, and the results w	ere as f	ollows	from men	nbers in		
		attendance (in favor, against, and a						
						·		
			Yes	No	Abst.			
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$					
		Kate Ward, Pharm.D., Vice Chair	$\boxtimes$					
		Joseph Adashek, MD			$\boxtimes$			
		Mark Crumby, Pharm.D.			$\boxtimes$			
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$					
		Sapandeep Khurana, MD	$\boxtimes$					

	<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>			$\boxtimes$		
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>	$\boxtimes$				
	Aditi Singh, MD			$\boxtimes$		
I. For Possible Action: Discussion						
and possible adoption of						
Phosphate Binding Agents.						
				.1 1 1		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.					
	No public comment was provided.					
ii. Drug class review	Dr. Deoliveira recommended the Bo	oard cor	nsider t	he class clinic	ally and	
presentation by Magellan	therapeutically equivalent.					
(Prime).						
iii. Discussion by Board and	Chairperson Decerbo moved to accept the class as clinically and					
action by Board to	therapeutically equivalent presente	•		•		
approve	Chairperson Ward seconded the mo	otion.				
clinical/therapeutic						
equivalency of agents in	A vote was taken, and the results w					
class.	attendance (in favor, against, and a	bstentio	ons wh	ere applicable	e):	
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
	Kate Ward, Pharm.D., Vice Chair	$\boxtimes$				
	Joseph Adashek, MD			$\boxtimes$		
	Mark Crumby, Pharm.D.			$\boxtimes$		
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
	Sapandeep Khurana, MD	$\boxtimes$				
	Isabella Niezborala, Pharm.D.			$\boxtimes$		
	Leana Ramirez, Pharm.D.	$\boxtimes$				
	Aditi Singh, MD			$\boxtimes$		

	1				
iv. Presentation of recommendations for PD inclusion by Magellan (Prime).	Dr. Deoliveira recommended moving pack from preferred to non-preferre generic sevelamer carbonate tablet a preferred to preferred.	d. Also	recom	mend moving its	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	presented by Magellan (Prime) and E the motion.  A vote was taken, and the results we	pard Member Ramirez moved to approve the proposed changes as resented by Magellan (Prime) and Board Member Khurana seconded be motion.  vote was taken, and the results were as follows from members in tendance (in favor, against, and abstentions where applicable):			
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	TC3 ⊠			
	Kate Ward, Pharm.D., Vice Chair	⊠			
	Joseph Adashek, MD			$\boxtimes$	
	Mark Crumby, Pharm.D.			$\boxtimes$	
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.			$\boxtimes$	
	Leana Ramirez, Pharm.D.	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
I. Magellan (Prime) Reports	New Drugs to Market and New Line  o elafibranor oral  o seladelpar oral  o midomafetamine oral  o xanomeline-trospium(Kar				
K. Closing Discussion					
i. Public comments on any subject	No public comments were provided.				

ii. Date and location of the next meeting.	Date: September 26, 2024 Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109	
iii. Adjournment	Chairperson Decerbo adjourned the meeting at 2:54 PM.	

## Attachment A - Members of the Public in Attendance

Kim EggertCarin HennesseyAaron GirvinAlice SwettRyan K BittonKaren Ou

Larry L Curtis Lynda Finch
Veronica Bean Jackie

Elisa Ashton [SCGUS] Tray Abney

Jeana Colabianchi Scribe (Belz & Case by Rewatch)

Greg Kitchens (Artia Solutions)

Amy Hale [JANUS]

Ferrari Reeder (Public Affairs)

Ryan A Roa

Kerisa Weaver

Lea Case

## Attachment B - Submitted Written Comment

No